Related references
Note: Only part of the references are listed.The Serotonin 1A (5-HT1A) Receptor as a Pharmacological Target in Depression
Alexander L. W. Smith et al.
CNS DRUGS (2023)
The 2020 Royal Australian and New Zealand College of psychiatrists clinical practice guidelines for mood disorders: Bipolar disorder summary
Gin S. Malhi et al.
BIPOLAR DISORDERS (2020)
The Effect of Gepirone-ER in the Treatment of Sexual Dysfunction in Depressed Men
Louis F. Fabre et al.
JOURNAL OF SEXUAL MEDICINE (2012)
Gepirone-ER Treatment of Hypoactive Sexual Desire Disorder (HSDD) Associated with Depression in Women
Louis F. Fabre et al.
JOURNAL OF SEXUAL MEDICINE (2011)
Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: A double-blind, randomized, placebo-controlled, parallel-group study
Robert J. Bielski et al.
JOURNAL OF CLINICAL PSYCHIATRY (2008)
Relapse prevention with gepirone ER in outpatients with major depression
MB Keller et al.
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2005)
Effects of food on the bioavailability of gepirone from extended-release tablets in humans: Results of two open-label crossover studies
LF Fabre et al.
CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL (2003)
Gepirone extended-release: New evidence for efficacy in the treatment of major depressive disorder
AD Feiger et al.
JOURNAL OF CLINICAL PSYCHIATRY (2003)
Single- and multiple-dose pharmacokinetics and tolerability of gepirone extended-release
CJ Timmer et al.
CLINICAL DRUG INVESTIGATION (2002)
Pharmacokinetics of gepirone in subjects with normal renal function and in patients with chronic renal dysfunction
P Dogterom et al.
CLINICAL DRUG INVESTIGATION (2002)
Share Paper
